Damora Therapeutics, Inc.
NASDAQ:DMRABiotechnology
+$0.07 today
- Market cap
- $1.42B
- Beta
- 1.48
- P/E (TTM)
- -0.1
- EPS (TTM)
- -$177.15
Volume 0.58M
Average 0.33M
Returns on capital
Damora Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-87.3%
avg -80.8%
ROIC
-87.7%
avg -73.7%
ROA
-80.5%
avg -70.3%
Analysis
ROA is currently the strongest return metric at -80.5% versus its period average of -70.3%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Garrett Winslow | Senior VP, General Counsel & Corporate Secretary | USD 827.8K | 47 | 2.29K | <0.01% |
Becker Hewes | Chief Medical Officer | — | 60 | — | — |
Sherwin Sattarzadeh | Chief Operating Officer | — | 47 | — | — |
Brian Burkavage | Senior VP of Finance, Principal Financial & Accounting Officer | — | 43 | 312.54K | 0.51% |
Hakon Leffler | Co-Founder | — | — | — | — |
Tariq Sethi FRCP | Co-Founder | — | — | — | — |
Jennifer A. Jarrett | CEO, President & Director | — | 55 | — | — |
Ulf J. Nilsson | Co-Founder | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 6, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$252,875.00
Sells
1
$7,345.10
Net Transaction Value
+$245,529.90
Net buying
Most Active
Jarrett Jennifer
1 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Sep 25, 26Sep 25, 2026 | Jarrett Jennifer Direct | Buy | $252.9K$252,875.00 |
| Jul 6, 26Jul 6, 2026 | Winslow Garrett Direct | Sell | $7.3K$7,345.10 |
Summary
Insiders reported 1 buys worth $252,875.00 and 1 sells worth $7,345.10 over the last 12 months. That adds up to net buying of $245,529.90. Jarrett Jennifer was the most active insider with 1 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Damora Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about DMRA's management, answered from reported figures.
Who manages DMRA?
Damora Therapeutics, Inc. (DMRA) lists 8 active executives. The top listed executive is Garrett Winslow, Senior VP, General Counsel & Corporate Secretary.
Are DMRA insiders buying or selling?
Recent insider activity shows net buying of $49.50M.
Continue the stock analysis
Jump to another research area for this company.